EMA starts rapid review of Bluebird’s gene therapy for rare disease CALDBluebird bio could be just a few months away from approval of its gene therapy for rare disease Share XEMA starts rapid review of Bluebird’s gene therapy for rare disease CALDhttps://pharmaphorum.com/news/ema-starts-rapid-review-of-bluebirds-gene-therapy-for-rare-disease-cald/
Life science leaders sign new ‘Biotech Social Pact’ for EuropeThe signatories of a new Biotech Social Pact with Europe and patients explain why healthcare calls for a Share XLife science leaders sign new ‘Biotech Social Pact’ for Europehttps://pharmaphorum.com/views-analysis-market-access/life-science-leaders-sign-new-biotech-social-pact-for-europe/
Time for a health innovation pact: rethinking the design and delivery of healthcareJanssen’s Anouk De Vroey on why we need to extend the public/private partnerships resulting from COVID-19 into more Share XTime for a health innovation pact: rethinking the design and delivery of healthcarehttps://pharmaphorum.com/views-and-analysis/time-for-a-health-innovation-pact-rethinking-the-design-and-delivery-of-healthcare/
How does HTA for orphan drugs differ across Europe?New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines Share XHow does HTA for orphan drugs differ across Europe?https://pharmaphorum.com/views-analysis-market-access/how-does-hta-for-orphan-drugs-differ-across-europe/
New digital health player HealthHero launches with Fernarzt buyThere’s a new kid on the block in digital health – called HealthHero – with aspirations to become Share XNew digital health player HealthHero launches with Fernarzt buyhttps://pharmaphorum.com/news/new-digital-health-player-healthhero-launches-with-fernarzt-buy/
Alnylam’s Anant Murthy on making it as a US biotech in EuropeAlnylam’s European head of market access and GM of mid-size markets, Anant Murthy, shares his perspective on how Share XAlnylam’s Anant Murthy on making it as a US biotech in Europehttps://pharmaphorum.com/r-d/views-analysis-r-d/alnylam-anant-murthy-on-making-it-as-a-us-biotech-in-europe/
AZ promises to deliver 400m doses of COVID-19 vaccine to EuropeAstraZeneca has followed through on its pledge to provide its COVID-19 vaccine at cost during the pandemic, saying Share XAZ promises to deliver 400m doses of COVID-19 vaccine to Europehttps://pharmaphorum.com/news/az-promises-to-deliver-400m-doses-of-covid-19-vaccine-to-europe/
European VCs ‘actively seeking new healthcare investments’The disruption caused by the coronavirus crisis hasn’t dampened the enthusiasm of European venture capitalists to make funding Share XEuropean VCs ‘actively seeking new healthcare investments’https://pharmaphorum.com/news/european-vcs-actively-seeking-new-healthcare-investments/
ECJ backs UK regulator’s ‘pay-for-delay’ fine levied on GSKThe top EU court has endorsed an earlier decision by the UK financial regulator to fine GlaxoSmithKline in Share XECJ backs UK regulator’s ‘pay-for-delay’ fine levied on GSKhttps://pharmaphorum.com/news/ecj-backs-uk-regulators-pay-for-delay-fine-levied-on-gsk/
